Since RANK/RANKL/OPG pathway is crucial in osteoclastogenesis, inhibition of RANKL is a possible therapeutic target to prevent erosions and bone mass loss in RA. This evidence concerns the gene TNFRSF11A and rheumatoid arthritis.